Related Experiment Videos
Necrotizing eccrine squamous syringometaplasia presenting as acral erythema
F Rongioletti1, A Ballestrero, F Bogliolo
1Department of Dermatology, University of Genoa, Italy.
Journal of Cutaneous Pathology
|December 1, 1991
Summary
Acral erythema (AE) and eccrine squamous syringometaplasia (ESS) are distinct conditions in chemotherapy patients. This case shows both AE and ESS in acute myelogenous leukemia, offering a diagnostic clue.
Area of Science:
- Dermatology
- Oncology
- Pathology
Background:
- Acral erythema (AE) and eccrine squamous syringometaplasia (ESS) are known clinico-pathological findings in patients undergoing chemotherapy.
- Chemotherapy-induced AE and ESS have typically been considered separate entities.
Observation:
- A patient with acute myelogenous leukemia receiving cytarabine chemotherapy presented with typical acral erythema.
- Histopathological examination of the skin lesions revealed concurrent eccrine squamous syringometaplasia.
Findings:
- This is the first reported case of chemotherapy-induced acral erythema with histopathologic evidence of eccrine squamous syringometaplasia.
- The presence of ESS in a patient with AE may serve as a key diagnostic indicator.
Implications:
- Distinguishing chemotherapy-induced AE from palmar-plantar erythema associated with graft-vs-host reactions is crucial for patient management.
- Recognizing the co-occurrence of AE and ESS can aid in accurate diagnosis and treatment strategies for cancer patients.